67 studies on Retatrutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 20,061 published Retatrutide COA source records from third-party laboratories, covering 2,698 publicly attributable vendor identities. Across 18,418 records with positive numeric purity, the arithmetic mean is 99.66%. 319 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 55 positive purity results are below 90%; 1,051 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-16. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $10.12 | $8.00–$13.00 | $2.02 | 4 sources · 4 offers |
| 10 mg | $12.33 | $10.50–$14.50 | $1.23 | 3 sources · 3 offers |
| 15 mg | $18.62 | $14.50–$26.00 | $1.24 | 4 sources · 4 offers |
| 20 mg | $23.25 | $17.50–$32.50 | $1.16 | 4 sources · 4 offers |
| 30 mg | $29.30 | $21.50–$39.00 | $0.98 | 5 sources · 5 offers |
| 40 mg | $35.00 | $28.00–$45.50 | $0.88 | 4 sources · 4 offers |
| 50 mg | $41.88 | $32.00–$52.00 | $0.84 | 4 sources · 4 offers |
| 60 mg | $39.83 | $35.00–$45.50 | $0.66 | 3 sources · 3 offers |
| 120 mg | $54.50 | $54.50–$54.50 | $0.45 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-16. Aggregate calculated: 2026-10-18T05:13:55.434922+00:00. Calculation time is not a laboratory observation date.
Within that total, 5479 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 157 | 99.69% | 0 of 137 (0.0%) 0 0% / not detected · 0 wrong compound · 20 unclassified | Reveal with Pro → | |
| #2 | 130 | 99.64% | 0 of 129 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #3 | 151 | 99.44% | 0 of 127 (0.0%) 0 0% / not detected · 0 wrong compound · 24 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120445 (99.75%) · #120444 (99.86%) · #120417 (99.83%) · #120392 (99.86%) · #120391 (99.85%) · #120307 (99.79%)
This study provides compelling evidence that dual and triple incretin agonists offer superior glycemic control and weight loss benefits compared to current GLP-1 receptor agonists for patients with Type 2 Diabetes. Th…
This study highlights the potential of retatrutide to not only manage blood glucose but also to directly address the underlying appetite dysregulation in type 2 diabetes and obesity. By improving appetite control and …
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
These advancements collectively represent a significant leap forward in nephrology, offering new hope for patients with various kidney conditions. The expansion of complement inhibitors and the efficacy of GLP-1 recep…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…
The findings from this Phase 1 study are critically important for the future development of LY3437943. Understanding the impact of hepatic impairment on drug pharmacokinetics is essential for establishing safe and eff…
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resm…
Free, no account — handy when you're working with Retatrutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account